美国食品药品监督管理局批准了伊莱利的新口服减肥药. FDA approves Eli Lilly's new oral weight-loss pill.

美国食品和药物管理局批准了Eli Lilly公司的口服减肥片orforglipron, 这是首次通过口服GLP-1药物获得慢性体重控制的批准. The FDA has approved orforglipron, an oral weight-loss pill from Eli Lilly, marking the first time an oral GLP-1 medication is approved for chronic weight management. 通过调节食欲,它有显著的减肥作用. It works by regulating appetite and was shown to significantly reduce weight in clinical trials. 常见的副作用包括恶心,腹和嘔吐. Common side effects include nausea, diarrhea, and vomiting.